Long noncoding RNA ZBED3-AS1 restrains breast cancer progression by targeting the microRNA-513a-5p/KLF6 axis

Aiqin Fu | Ze Yu | Enning Zhang | Jijie Song

1Department of Medical Oncology, Yantai Yantai City, China
2Department of General Surgery, Yantai Municipal Laiyang Central Hospital, Yantai City, China

Correspondence
Jijie Song, Department of General Surgery, Yantai Municipal Laiyang Central Hospital, No. 111, Changshan Road, Yantai City, Shandong Province, 265200, China. Email: songjijie257@163.com

Abstract
Breast cancer (BC) is the most commonly occurring malignancy in women. This study aimed to investigate the functions of the long noncoding RNA ZBED3-AS1 (ZBED3-AS1) in BC and its molecular mechanisms. qRT-PCR was conducted to access the expression of ZBED3-AS1, microRNA-513a-5p (miR-513a-5p), and Kruppel like factor 6 (KLF6) in BC. Additionally, BC cell viability and proliferative capacity were measured by MTT and 5-Ethynyl-20-deoxyuridine (EdU) assays. A transwell assay was used for evaluating BC cell migration and invasion. The interactions among ZBED3-AS1, miR-513a-5p, and KLF6 in BC were confirmed by dual-luciferase reporter assay. Furthermore, feedback approaches were performed to determine whether ZBED3-AS1 influences BC cell behaviors by regulating the miR-513a-5p/KLF6 axis. The murine xenograft model was established to assess the effect of ZBED3-AS1 on tumor growth. The expression of ZBED3-AS1 and KLF6 was reduced, while miR-513a-5p expression was elevated in BC. ZBED3-AS1 elevation attenuated the malignant behaviors of BC cells, including viability, proliferative capacity, migration, and invasion. Mechanical experiments revealed that ZBED3-AS1 targeted miR-513a-5p, and miR-513a-5p targeted KLF6 in BC. Feedback approaches validated that miR-513a-5p overexpression or KLF6 depletion reversed the inhibitory effects of ZBED3-AS1 upregulation on viability, proliferative capacity, migration, and invasion of BC cells. Furthermore, ZBED3-AS1 elevation attenuated the tumor growth in the murine xenograft model. ZBED3-AS1 hindered the malignant development of BC cells by regulating the miR-513a-5p/KLF6 axis, providing a novel therapeutic target in BC.

KEYWORDS
breast cancer, KLF6, long noncoding RNA ZBED3-AS1, microRNA-513a-5p, viability

INTRODUCTION
Breast cancer (BC) ranks second among causes for cancer-related death in women. Early BC is considered potentially curable. However, it is diagnosed in their advanced stages due to the negligence of women regarding the self inspection and clinical examination of the breast. Despite advances made in diagnostic and clinical therapeutic methods, the prognosis of BC patients is still unsatisfactory. In recent years, novel targeted therapies have been used in the treatment of BC and there is an urgent need to explore new genetic targets for BC therapy.

Long noncoding RNAs (lncRNAs) participate in diverse gynecological cancers, such as ovarian cancer, cervical cancer, and BC. It has been documented that certain lncRNAs attenuate the tumorigenesis of BC. Qin et al. have determined that lncRNA on chromosome 8p12 represses the proliferation capacity of BC cells. Kim et al. have demonstrated that lncRNA metastasis-associated lung adenocarcinoma transcript 1 retards the metastasis of BC. ZBED3-AS1 has been found to be involved in the regulation of stem cell chondrogenesis. Notably, Cui et al. have reported that ZBED3-AS1 is revealed to be associated with BC through preliminary bioinformatics...
analysis. However, the precise function of ZBED3-AS1 in the progression of BC remains unclear.

Numerous microRNAs (miRNAs) have been confirmed to exert a tumor-promoting effect in BC. For instance, miR-455-5p is upregulated in BC and accelerates cell invasion and migration. MiR-146a enhances the proliferation and metastasis of BC cells by suppressing NM2-H1. Previous research has reported that miR-513a-5p often functions as an onco-miR in diverse cancers. MiR-513a-5p overexpression enhances proliferation and attenuates apoptosis of nephroblastoma cells. A high miR-513a-5p level inhibits glioma cell sensitivity to temozolomide. Notably, lncRNA ADAMTS9-AS1 attenuates the aggressive phenotypes of BC cells through downregulating miR-513a-5p. However, the specific regulatory relationship between ZBED3-AS1 and miR-513a-5p in BC remains undefined.

KLF6, a member of the KLFs family, plays a pivotal role in biological processes, such as proliferation, differentiation, and metabolism. KLF6 often acts as an anti-oncogene in diverse cancers. For instance, KLF6 attenuates oral cancer migration and invasion by inhibiting mesenchymal marker and MMP-9 activities. LncRNA CR749391 interacts with miR-181a to enhance KLF6 expression, hampering the malignant development of gastric cancer cells. Importantly, KLF6 suppresses estrogen receptor-mediated cell growth in BC by targeting c-Scr. However, the relationship between ZBED3-AS1 and KLF6 in BC is still unknown.

Here, ZBED3-AS1 expression was evaluated in BC. The effects of ZBED3-AS1 on the malignant behaviors of BC cells were assessed. We explored whether miR-513a-5p is a target of ZBED3-AS1 and the relationship between miR-513a-5p and KLF6 in BC. This study may reveal molecular mechanisms and offer a new therapeutic target for BC.

MATERIAL AND METHOD

Clinical samples

A total of 17 BC patients who underwent mastectomy from January 2018 to January 2020 at our hospital were recruited to the study. BC tissues (n = 17, tumor group) and paired adjacent nontumor tissues (n = 17, normal group) were stored at −80°C. Prior to mastectomy, no radiotherapy or chemotherapy treatment was administered to the patients. This study was permitted by the Yantaishan Hospital Ethics Committee (approval no. 2016018), and informed consent was obtained from all participants.

Bioinformatics analysis

The gene expression analysis for the cancer genome atlas (TCGA) or GSE15852 cohort of BC was obtained from gene expression profiling interactive analysis 2 (GEPIA2) or the gene expression omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/), respectively. Kaplan–Meier analysis of the overall survival of BC patients was downloaded from GENT2. StarBase and LncBase were used for predicting the miRNAs that target ZBED3-AS1. Four miRNAs were identified by both prediction tools. The expression of miR-513a-5p was significantly higher in both MDA-MB-468 and MCF7 cells than in MCF-10A cells. Thus, miR-513a-5p was selected as the candidate miRNA for further experiments. TargetScan was employed to predict the target of miR-513a-5p, one of which was Kruppel like factor 6 (KLF6). KLF6 is a well-known anti-oncogene and is downregulated in BC cells. Thus, KLF6 was selected for following research.

Cell culture

Human breast epithelial cell line MCF-10A and four BC cell lines, MCF7, MDA-MB-231, MDA-MB-468, and MDA-MB-453 (American Type Culture Collection, Manassas, VA, USA), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplied with 10% fetal bovine serum (FBS, Invitrogen) at 37°C with 5% CO2.

Cell transfection

The pcDNA3.1 (pcDNA)-ZBED3-AS1, pcDNA-negative control (NC), miR-513a-5p mimics, miR-513a-5p inhibitor, mimics NC (miR-NC), inhibitor NC, short hairpin (sh)-KLF6, and sh-NC were synthesized by GenePharma. MDA-MB-468 and MCF7 cells grown to 80% confluence were transfected or co-transfected with these agents using Lipofectamine 3000 reagent (Invitrogen). After 48 h of transfection, MDA-MB-468 and MCF7 cells were used for further studies.

qRT-PCR and western blot

Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot procedures were conducted as previously

| Name of primer | Sequence (5’–3’) |
|---------------|-----------------|
| ZBED3-AS1-F    | TACAACCTTGGATTAACCTTCC |
| ZBED3-AS1-R    | TGCCCTGTCTCTATGTTCG |
| GAPDH-F        | CATGAGAAGTATGACAACAGCCT |
| GAPDH-R        | AGTCCTTCCAGATACCAAAGT |
| miR-513a-5p-F  | TAAAATTTCACCTTTCTGAGAAGG |
| miR-513a-5p-R  | GCGAGCACAGAATTAATACGAC |
| U6-F           | CTCGGTTCCAGCAGCA |
| U6-R           | AAGCGTCTCGAAGATTTGCT |
| KLF6-F         | AGTATTACCAGGCCACTTCCG |
| KLF6-R         | CTATTAGGCCAGCCACTTCC |
| β-actin-F      | CGACACACAAAGCACAGAG |
| β-actin-R      | GAATCAATCCAAAGTACCC |
described.23 The primers are listed in Table 1. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), RN6-U6-1 (U6), and β-actin were used for normalizing the expressions of ZBED3-AS1, miR-513a-5p, and KLF6, respectively. The antibodies for western blot analysis were anti-KLF6 (1:1000, av35639; Sigma) and anti-β-actin (1:1000, MABT523; Sigma) primary antibody, and HRP conjugate secondary antibody (1:5000, 12-348; Sigma). ImageLab software (Bio-Rad) was utilized to quantify the density of each band.

### MTT assay

MTT assay was performed to evaluate cell viability. MDA-MB-468 and MCF7 cells (2 x 10^5/well) were seeded in 96-well plates and incubated with 5% CO₂ at 37°C. At different time points (0, 24, 48, 72, and 96 h post-transfection), 10 μl of MTT (5 mg/ml; Sigma) was added to each well and cells were cultured for another 4 h, then the absorbance was measured at 450 nm.

### EdU assay

5-Ethynyl-2-deoxyuridine (EdU) assay were performed to assess cell proliferation. MDA-MB-468 and MCF7 cells (2 x 10^5/well) were seeded in 96-well plates and incubated in EdU solution (50 nmol/l) for 2 h and then visualized. A fluorescence microscope was used to obtain images.

### Cell migration and invasion

An invasion assay was conducted using a 24-well invasion chamber system coated with 50 μl Matrigel (Sigma). MDA-MB-468 and MCF7 cells (1 x 10^5 cells/well) suspended in serum-free medium were seeded into a precoated upper chamber. Medium supplement with 10% fetal bovine serum (FBS) was plated into the lower chamber. The invaded MDA-MB-468 and MCF7 cells were dyed using crystal violet after 24 h of cultivation, and then counted. For the assessment of migration,
FIGURE 2 Overexpressed ZBED3-AS1 inhibited the proliferation, migration, and invasion, but promoted apoptosis of breast cancer (BC) cells. (a) The transfection efficiency of pcDNA-NC and pcDNA-ZBED3-AS1 in MDA-MB-468 and MCF7 cells was measured by qRT-PCR, \( p < 0.01 \) versus pcDNA-NC. (b) and (c) The viability and proliferative capacity of MDA-MB-468 and MCF7 cells were analyzed by MTT and EdU assays, \( p < 0.01 \) versus pcDNA-NC. (d) and (e) The migration and invasion of MDA-MB-468 and MCF7 cells were measured by transwell assay, \( p < 0.01 \) versus pcDNA-NC. (f) The apoptosis of MDA-MB-468 and MCF7 cells was measured by flow cytometry analysis, \( p < 0.01 \) versus pcDNA-NC.
MDA-MB-468 and MCF7 cells were seeded into the non-coated upper chamber and the other steps were same as above.

Flow cytometry analysis

The apoptosis of MDA-MB-468 and MCF7 cells was assessed by flow cytometric analysis. Briefly, the collected BC cells (1 × 10^5 cells/ml) were cultured in 96-well plates for 24 h and then stained with annexin V-fluorescein isothiocyanate and propidium iodide using an apoptosis detection kit (Thermo Fisher Scientific) at 25°C for 20 min in the dark. The apoptotic cells were measured using a flow cytometer (BD Biosciences).

Murine xenograft tumor model

Ten female BALB/c nude mice (4-week-old) were purchased from Esebio. The animal experiments and programs were approved by the Animal Care and Use Committee of Yantaishan Hospital. MDA-MB-468 cells (5 × 10^6 cells) infected with lentiviral vector containing ZBED3-AS1 (lv-ZBED3-AS1) or empty lentiviral vector (lv-NC) were intraperitoneally injected into mice (n = 5 per group). Tumor volume was detected 1 week after inoculation and calculated using the following formula: 1/2LW^2 (L, length; W, width). After the last measurement at the fourth week, mice were anesthetized and sacrificed by cervical dislocation, and the tumor was weighted.
Dual-luciferase reporter assay

We generated ZBED3-AS1 and KLF6 sequences with wild type (WT) or mutant type miR-513a-5p-binding sites and cloned them in pGL3-Basic vectors (Ke Lei Biological Technology). MDA-MB-468 and MCF7 cells were co-transfected with above luciferase vectors and miR-NC or miR-513a-5p mimics by Lipofectamine 3000 (Invitrogen).

Statistical analyses

GraphPad Prism 8.0 was used for statistical analyses. Data were presented as the mean ± SD. Variances among groups were compared by Student’s t-test or one-way ANOVA followed by Tukey’s multiple comparisons test. The significance of the correlations was evaluated by Pearson’s correlation analysis. p values <0.05 indicated statistically significance.

RESULTS

ZBED3-AS1 was considerably inhibited in BC

As shown in Figure 1(a), the ZBED3-AS1 expression in 1085 BC tumor tissues was found to be lower than that in 291 normal breast tissues by using TCGA database. In addition, the dataset GSE15852 showed that ZBED3-AS1 expression in BC tumor tissues (n = 43) was considerably downregulated compared with that in paired normal tissues (n = 43) (p = 0.0047; Figure 1(b)). The Kaplan–Meier curve showed that the survival percentage of BC patients with higher ZBED3-AS1 expression (n = 219) was markedly better than that in the lower expression group (n = 283) (logrank p = 0.002; Figure 1(c)). The ZBED3-AS1 expression in BC tissues was evidently decreased compared with the adjacent nontumor tissues (p < 0.001; Figure 1(d)).

FIGURE 4 MiR-513a-5p was a target of ZBED3-AS1. (a) MiR-513a-5p was predicted to be a potential ZBED3-AS1 target via StarBase and LncBase. (b) The expression of miR-382-5p, miR-506-5p, miR-513a-5p, and miR-134-5p was detected by qRT-PCR in MCF-10A, MDA-MB-468, and MCF7 cells, *p < 0.01 versus MCF-10A. (c) Starbase exhibited the predicted binding site between ZBED3-AS1 and miR-513a-5p. (d) The expression of miR-513a-5p was decreased by the transfection of pcDNA-ZBED3-AS1 in MDA-MB-468 and MCF7 cells, *p < 0.01 versus pcDNA-NC. (e) Relative luciferase activity in MDA-MB-468 and MCF7 cells was assessed by dual-luciferase reporter assay, *p < 0.01 versus miR-NC. (f) qRT-PCR was performed to detect the expression of miR-513a-5p in breast cancer (BC) tissues and adjacent nontumor tissues, *p < 0.001 versus adjacent tissues. (g) The expression of ZBED3-AS1 was negatively correlated with miR-513a-5p in BC patients.
metastasis (LMN)-positive patients was lower than that in LMN-negative patients ($p = 0.0038$; Figure 1(e)). Moreover, ZBED3-AS1 expression was markedly decreased in MCF7, MDA-MB-231, MDA-MB-468, and MDA-MB-453 cells compared with MCF-10A cells ($p < 0.01$; Figure 1(f)).

**Overexpressed ZBED3-AS1 inhibited the proliferation, migration, and invasion, but promoted apoptosis of BC cells**

We then explored the possible role of ZBED3-AS1 in BC progression in vitro by transfection of pcDNA-
**ZBED3-AS1 in MDA-MB-468 and MCF7 cells.** As shown in Figure 2(a), ZBED3-AS1 was effectively upregulated after pcDNA-ZBED3-AS1 transfection in MDA-MB-468 and MCF7 cells ($p < 0.01$). MTT and EdU assays revealed that ZBED3-AS1 overexpression clearly suppressed MDA-MB-468 and MCF7 cell viability and proliferative capacity, respectively ($p < 0.01$; Figure 2(b),(c)). Additionally, the transwell assay showed that ZBED3-AS1 upregulation could visibly reduce MDA-MB-468 and MCF7 cell migration and invasion, respectively ($p < 0.01$; Figure 2(d),(e)). We further found that overexpression of ZBED3-AS1 promoted the apoptosis of MDA-MB-468 and MCF7 cells ($p < 0.01$; Figure 2(f)).

**ZBED3-AS1 overexpression attenuated the tumorigenesis of BC**

The functions of ZBED3-AS1 on the tumorigenesis of BC in vivo were also investigated. As illustrated in Figure 3(a), ZBED3-AS1 overexpression could markedly decrease the tumor weight and volume at the fourth week after injection ($p < 0.01$; Figure 3(a)). In addition, the expression levels of ZBED3-AS1, miR-513a-5p, and KLF6 in BC tissues of mice were detected. As presented in Figure 3(b)–(d), we demonstrated that after injection with Lv-ZBED3-AS1, the expressions of ZBED3-AS1 and protein level of KLF6 were elevated, and miR-513a-5p expression was repressed ($p < 0.01$).
**FIGURE 7**  ZBED3-AS1 overexpression restrained the malignant behaviors of MDA-MB-468 cells by regulating the miR-513a-5p/KLF6 axis. (a) Western blot was performed to measure the protein expression of KLF6 in MDA-MB-468 cells, **"p < 0.01 versus pcDNA-NC.** ""p < 0.01 versus pcDNA-ZBED3-AS1. (b) The transfection efficiency of sh-NC and sh-KLF6 was measured by qRT-PCR in MDA-MB-468 cells, **"p < 0.01 versus sh-NC.** (c)-(f) Upregulation of miR-513a-5p or downregulation of KLF6 reversed the inhibitory effects of ZBED3-AS1 overexpression on viability, proliferative capacity, migration, and invasion of MDA-MB-468 cells, **"p < 0.01 versus pcDNA-NC.** ""p < 0.01 versus pcDNA-ZBED3-AS1

**MiR-513a-5p is a target of ZBED3-AS1**

The miR-382-5p, miR-506-5p, miR-513a-5p, and miR-134-5p were predicted to be the potential ZBED3-AS1 targets according to StarBase and LncBase (Figure 4(a)). Among these potential ZBED3-AS1 targets, only the expression of miR-513a-5p was significantly higher in both MDA-MB-468 and MCF7 cells than in MCF-10A cells (p < 0.01;
We therefore selected miR-513a-5p as the candidate miRNA for subsequent studies. StarBase showed that ZBED3-AS1 contained the target site of miR-513a-5p (Figure 4(c)). ZBED3-AS1 overexpression could evidently repress miR-513a-5p expression in MDA-MB-468 and MCF7 cells ($p < 0.01$; Figure 4(d)). The dual-luciferase reporter assay revealed that miR-513a-5p upregulation effectively hindered the activity of WT-ZBED3-AS1 reporter in MDA-MB-468 and MCF7 cells ($p < 0.01$; Figure 4(e)). Furthermore, miR-513a-5p expression was dramatically elevated in BC tissues compared to adjacent nontumor tissues ($p < 0.001$; Figure 4(f)). An inverse expression correlation...
between ZBED3-AS1 and miR-513a-5p was found in BC patients ($r = -0.3643$, $p = 0.0015$; Figure 3(g)).

**MiR-513a-5p suppression retards the tumorigenesis of BC cells**

Figure 5(a) shows that miR-513a-5p expression was clearly enhanced or attenuated following miR-513a-5p mimics or miR-513a-5p inhibitor transfection in MDA-MB-468 and MCF7 cells ($p < 0.01$). MiR-513a-5p suppression considerably weakened the viability and proliferative capacity of MDA-MB-468 and MCF7 cells ($p < 0.01$; Figure 5(b),(c)). In parallel, miR-513a-5p deficiency could visibly attenuate the migration and invasion of MDA-MB-468 and MCF7 cells ($p < 0.01$; Figure 5(d),(e)).

**KLF6 was a target of miR-513a-5p**

TargetScan showed that miR-513a-5p binds to the 3′-untranslated region of KLF6 (Figure 6(a)). The dual-luciferase reporter assay determined that miR-513a-5p overexpression effectively inhibited the activity of WT-KLF6 luciferase reporter assay determined that miR-513a-5p overexpression suppressed the translational capacity of KLF6 (Figure 6(a)). The dual-luciferase reporter assay determined that miR-513a-5p overexpression suppressed the translational capacity of KLF6 (Figure 6(a)). In parallel, miR-513a-5p deficiency could visibly attenuate the migration and invasion of MDA-MB-468 and MCF7 cells ($p < 0.01$; Figure 6(d),(e)).

**ZBED3-AS1 overexpression restrained the malignant behaviors of BC cells by regulating the miR-513a-5p/KLF6 axis**

ZBED3-AS1 overexpression could clearly enhance the KLF6 protein expression in MDA-MB-468 cells, and miR-513a-5p overexpression mitigated this effect ($p < 0.01$; Figure 7(a)). After sh-KLF6 transfection, KLF6 expression was effectively suppressed in MDA-MB-468 cells ($p < 0.01$; Figure 7(b)). Feedback approaches were conducted to determine whether ZBED3-AS1 exerts its functions by targeting the miR-513a-5p/KLF6 axis. As shown in Figure 7(c)–(f), miR-513a-5p elevation or KLF6 depletion considerably reversed the suppressive effects of ZBED3-AS1 overexpression on the viability, proliferative capacity, migration, and invasion of MDA-MB-468 cells ($p < 0.01$). As expected, similar results were observed in MCF7 cells (Figure 8(a)–(f)).

**DISCUSSION**

It has been documented that the expression of lncRNAs such as AY343892, XIST, and TUBA4B is downregulated and associated with the tumorigenesis of BC. In the present study, ZBED3-AS1 expression was considerably suppressed in BC tissues and cells. In addition, ZBED3-AS1 expression was found to be correlated with lymph node metastasis (LNM) in BC patients, and low expression of ZBED3-AS1 brought out an adverse function in survival. Previous studies have demonstrated that certain lncRNAs are downregulated and related to poor prognosis in BC. For instance, a low lncRNA NBT1 level is associated with LNM as well as with poor patient survival in BC. LncRNA LINC01133 reduction is significantly correlated with LNM and advanced tumor node metastasis stage in BC patients. The expression of LINC00641 is lower in patients with a higher stage of BC and patients with LNM. Taken together, these data implied that ZBED3-AS1 may be involved in the progression of BC.

Numerous studies have confirmed that lncRNA takes part in the cellular processes of BC. For instance, lncRNA MAGI2-AS3 overexpression represses BC cell migration and invasion through downregulating miR-374a and upregulating phosphatase and tensin homolog deleted on chromosome ten. LncRNA LOXL1-AS1 negatively regulates miR-143-3p to attenuate the proliferation and enhance apoptosis of BC cells. LncRNA MIR503HG upregulation represses miR-103 to enhance OLFM4 expression, retarding the malignant development of BC. In this study, ZBED3-AS1 overexpression attenuated BC cell viability, proliferative capacity, invasion, and migration. The roles of ZBED3-AS1 were similar to those found in the aforementioned studies, indicating that ZBED3-AS1 may function as an oncogene in the development of BC. Additionally, certain lncRNAs act as tumor suppressors in BC, and lncRNA elevation causes the inhibition of tumor growth in vivo. For instance, lncRNA MEG3 overexpression significantly inhibits breast tumor xenograft growth in vivo. Elevated of lncRNA LINC00968 reduces the BC tumor volume and weight in mice by inhibiting miR-423-5p. Similarly, ZBED3-AS1 overexpression constrains tumor growth in mice, determining the critical role of ZBED3-AS1 in attenuating BC tumorigenesis in vivo. Above all, ZBED3-AS1 may be a promising therapeutic target for BC.

Certain lncRNAs regulate miRNAs expression to exert its anti-oncogenic effect in BC. For instance, lncRNA LIN00899 alleviates malignant tumor behavior in BC through downregulating miR-425. LncRNA XIST upregulation exerts anti-proliferation and pro-apoptosis effects in BC cells by inhibiting miR-326-5p. Importantly, lncRNA ADAMTS9-AS1 overexpression inhibits miR-513a-5p to attenuate the aggressive traits of BC cells. In the present study, we revealed that ZBED3-AS1 is a target of miR-513a-5p and is negatively related to miR-513a-5p expression, suggesting that ZBED3-AS1 may be involved in BC by restraining miR-513a-5p. Furthermore, miR-513a-5p is highly expressed and acts as an onco-miR in different cancers. For instance, miR-513a-5p
upregulation weakens the tumor suppressor function of cCNTNAP3 in esophageal squamous cell carcinoma.\textsuperscript{37} MiR-513a-5p elevation accelerates the tumorigenesis of nephroblastoma cells.\textsuperscript{36} Notably, miR-513a-5p functions as an oncogene in BC by targeting progesterone receptors.\textsuperscript{38} Here, we determined that miR-513a-5p deficiency attenuated the malignant development of BC cells, and miR-513a-5p elevation reversed the antitumor roles of ZBED3-AS1 in BC cells. Taken together, ZBED3-AS1 overexpression may constrain the malignant tumor behavior of BC cells by downregulating miR-513a-5p.

KLF6 is often downregulated in diverse tumors, such as colorectal cancer,\textsuperscript{39} ovarian cancer,\textsuperscript{40} and BC.\textsuperscript{41} Similarly, KLF6 like genes.\textsuperscript{42} KLF6 exerts antigrowth and pro-apoptosis functions.\textsuperscript{43} KLF6 may be an anti-oncogene in BC. KLF6 attenuates the expression by inhibiting miR-513a-5p in BC. The feedback data revealed that KLF6 depletion reversed the antitumor effect of miR-513a-5p, we suspect that ZBED3-AS1 may elevate KLF6 expression in BC cells by regulating the miR-513a-5p/KLF6 axis. In conclusion, ZBED3-AS1 expression was suppressed in BC tissues and cells. Additionally, miR-513a-5p is a target of ZBED3-AS1, and KLF6 is a target of miR-513a-5p. Moreover, ZBED3-AS1 restrained the malignant development of BC cells by regulating the miR-513a-5p/KLF6 axis. ZBED3-AS1 may be a potential therapeutic target for BC.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

ORCID

Jijie Song \(\text{https://orcid.org/0000-0001-6164-0106}\)

REFERENCES

1. Fahad UM. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64.
2. Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–50.
3. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50:17–10.
4. Solanki M, Visscher D. Pathology of breast cancer in the last half century. Hum Pathol. 2020;95:137–48.
5. Greenwood I, Zaza N, Das S, Li BD. Precision medicine and targeted therapies in breast cancer. Surg Oncol Clin N Am. 2020;29:51–62.
6. Li J, Yang C, Li Y, Chen A, Li L, You Z. LncRNA GASS suppresses ovarian cancer by inducing inflammation. Biosci Rep. 2018;38:11.
7. Fan Y, Sheng W, Meng Y, Cao Y, Li R. LncRNA PTENP1 inhibits cervical cancer progression by suppressing miR-106b. Artif Cells Nanomed Biotechnol. 2020;48:393–407.
8. Ma F, Liu X, Zhou S, et al. Long non-coding RNA FGF13-AS1 inhibits glycolysis and stemness properties of breast cancer cells through FGF13-AS1/IGF2BPs/Myf feedback loop. Cancer Lett. 2019;450:63–75.
9. Qin CX, Yang XQ, Jin GC, Zhan ZY. LncRNA TSLNC8 inhibits proliferation of breast cancer cell through the miR-214-3p/FOX2P axis. Eur Rev Med Pharmacol Sci. 2019;23:8480–8.
10. Kim J, Piao HL, Kim BJ, et al. Long noncoding RNA MALAT1 suppresses breast cancer metastasis. Nat Genet. 2018;50:1705–15.
11. Ou F, Su K, Sun J, et al. The LncRNA ZBED3-AS1 induces chondrogenesis of human synovial fluid mesenchymal stem cells. Biochem Biophys Res Commun. 2017;487:63–63.
12. Hu K, Jiang W, Sun H, Li Z, Rong G, Yin Z. Long noncoding RNA ZBED3-AS1 induces the differentiation of mesenchymal stem cells and enhances bone regeneration by repressing IL-1β via Wnt/β-catenin signaling pathway. J Cell Physiol. 2019;234:17863–75.
13. Cui Y, Fan Y, Zhao G, et al. Novel LncRNA PSMD3-A5 functions as a miR-143-3p sponge to increase the proliferation and migration of breast cancer cells. Oncol Rep. 2020;43:229–39.
14. Ali T, Paizula A, Ayoufu A. miR-455-3p promotes cell invasion and migration in breast cancer. Mol Med Rep. 2018;17:1825–32.
15. Chen J, Jiang Q, Jiang XQ, et al. miR-146a promoted breast cancer proliferation and invasion by regulating NM23-H1. J Biochem. 2020;167:41–8.
16. Zhao JL, Zhao LL, Niu WZ, Ding XC, Zhang WL. Deleted in lymphocytic leukemia 1 promoted proliferation and apoptosis of nephroblastoma cells through regulating miR-513a-5p and RANBP2 pathway. Zhonghua Zhong Liu Za Zhi. 2020;42:849–55.
17. Chen KC, Chen PH, Ho KH, et al. IGF-1-enhanced miR-513a-5p signaling desensitizes glioma cells to temozolomide by targeting the NEDD4L-inhibited Wnt/β-catenin pathway. PLoS One. 2019;14:e0225913.
18. Fang S, Zhao Y, Hu X. LncRNA ADAMTS9-S1 restrains the aggressive traits of breast carcinoma cells via sponging miR-513a-5p. Cancer Manag Res. 2020;12:10693–703.
19. Syafuddin SE, Mohtar MA, Wan Mohamad Nazarie WF, Low TY. Two sides of the same coin: the roles of KLF6 in physiology and pathophysiology. Biomolecules. 2020;10:1378.
20. Hsu LS, Huang RH, Lai HW, et al. KLF6 inhibited oral cancer migration and invasion via downregulation of mesenchymal markers and inhibition of MMP-9 activities. Int J Med Sci. 2017;14:530–5.
21. Shi S, Li D, Li Y, Feng Z, Du Y, Nie Y. LncRNA CR7/49391 acts as a tumor suppressor to upregulate KLF6 expression via interacting with miR-181a in gastric cancer. Exp Ther Med. 2020;19:569–78.
22. Liu J, Du T, Yuan Y, He Y, Tan Z, Liu Z. KLF6 inhibits estrogen receptor-mediated cell growth in breast cancer via a c-Src-mediated pathway. Mol Cell Biochem. 2010;335:29–35.
23. Li X, Deng S, Pang X, et al. LncRNA NEAT1 silenced miR-133b promotes migration and invasion of breast cancer cells. Int J Mol Sci. 2019;20:3616.
24. Li Y, Zhang M, Li F. LncRNA AY343892 inhibits breast cancer development by positively regulating BRCA1-mediated transcription of PTEN. Histol Histopathol. 2020;35:1171–80.
25. Zheng R, Lin S, Guan L, et al. Long non-coding RNA XIST inhibited breast cancer cell growth, migration, and invasion via miR-155/CDX1 axis. Biochem Biophys Res Commun. 2018;498:1002–8.
26. Liu AX, Yang F, Huang L, Zhang LY, Zhang JR, Zheng RN. Long non-coding RNA tubulin alpha 4B (TUBA4B) inhibited breast cancer proliferation and invasion by directly targeting miR-19. Eur Rev Med Pharmacol Sci. 2019;23:705–15.
27. Hu P, Chu J, Wu Y, et al. NBTAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. Oncotarget. 2015;6:32410–25.
28. Song Z, Zhang X, Lin Y, Wei Y, Liang S, Dong C. LINC01133 inhibits breast cancer invasion and metastasis by negatively regulating SOX4 expression through EZH2. J Cell Mol Med. 2019;23:7554–65.
29. Mao Q, Lv M, Li L, et al. Long intergenic noncoding RNA 00641 inhibits breast cancer cell proliferation, migration, and invasion by sponging miR-194-5p. J Cell Physiol. 2020;235:2668–75.
30. Du S, Hu W, Zhao Y, et al. Long non-coding RNA MAGI2-AS3 inhibits breast cancer cell migration and invasion via sponging microRNA-374a. Cancer Biomark. 2019;24:269–77.

31. Li GH, Yu JH, Yang B, Gong FC, Zhang KW. LncRNA LOXL1-AS1 inhibited cell proliferation, migration and invasion AS well as induced apoptosis in breast cancer via regulating miR-143-3p. Eur Rev Med Pharmacol Sci. 2019;23:10400–9.

32. Fu J, Dong G, Shi H, et al. LncRNA MIR503HG inhibits cell migration and invasion via miR-103/OLFM4 axis in triple negative breast cancer. J Cell Mol Med. 2019;23:4738–45.

33. Zhang Y, Wu J, Jing H, Huang G, Sun Z, Xu S. Long noncoding RNA MEG3 inhibits breast cancer growth via upregulating endoplasmic reticulum stress and activating NF-kB and p53. J Cell Biochem. 2019;120:6789–97.

34. Sun X, Huang T, Zhang C, et al. Long non-coding RNA LINC00968 reduces cell proliferation and migration and angiogenesis in breast cancer through up-regulation of PROX1 by reducing hsa-miR-423-5p. Cell Cycle. 2019;18:1908–24.

35. Zhou W, Gong J, Chen Y, et al. Long noncoding RNA LINC00899 suppresses breast cancer progression by inhibiting miR-425. Aging. 2019;11:10144–53.

36. Liu B, Luo C, Lin H, Ji X, Zhang E, Li X. Long noncoding RNA XIST acts as a ceRNA of miR-362-5p to suppress breast cancer progression. Cancer Biother Radiopharm. 2021;36:456–66.

37. Wang H, Song X, Wang Y, et al. CircCNTNAP3-TP53-positive feedback loop suppresses malignant progression of esophageal squamous cell carcinoma. Cell Death Dis. 2020;11:20–3217.

38. Muti F, Donzelli S, Sacconi A, et al. MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the Hormone and diet in the ETiology of breast cancer prospective study. Carcinogenesis. 2018;39:98–108.

39. Zhang B, Guo DD, Zheng JY, Wu YA. Expression of KLF6-SV2 in colorectal cancer and its impact on proliferation and apoptosis. Eur J Cancer Prev. 2018;27:20–6.

40. Li Y, Hou CZ, Dong YL, Zhu L, Xu H. Long noncoding RNA LINP1 promoted proliferation and invasion of ovarian cancer via inhibiting KLF6. Eur Rev Med Pharmacol Sci. 2020;24:36–42.

41. Ozdemir F, Koksal M, Ozmen V, Aydin I, Buyru N. Mutations and Krüppel-like factor 6 (KLF6) expression levels in breast cancer. Tumour Biol. 2014;35:5219–25.

42. Masilamani AP, Ferrarese R, Kling E, et al. KLF6 depletion promotes NF-κB signaling in glioblastoma. Oncogene. 2017;36:3562–75.

43. Jianwei Z, Enzhong B, Fan L, Jian L, Ning A. Effects of Kruppel-like factor 6 on osteosarcoma cell biological behavior. Tumour Biol. 2013;34:1097–105.

44. Wang K, Ren Y, Liu Y, Zhang J, He JI. miR-4262 promotes proliferation and invasion of human breast cancer cells through directly targeting KLF6 and KLF15. Oncol Res. 2017;25:277–83.

45. Liu Y, Cheng T, Du Y, Hu X, Xia W. LncRNA LUCAT1/miR-181a-5p axis promotes proliferation and invasion of breast cancer via targeting KLF6 and KLF15. BMC Mol Cell Biol. 2020;21:20–310.

How to cite this article: Fu A, Yu Z, Zhang E, Song J. Long noncoding RNA ZBED3-AS1 restrains breast cancer progression by targeting the microRNA-513a-5p/KLF6 axis. Thorac Cancer. 2021;12:2719–31. https://doi.org/10.1111/1759-7714.14111